Abstract
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have